Everolimus (Afinitor®)
Phase 2CompletedDevelopment Stage
Poorly Differentiated Malignant Neuroendocrine Carcinoma
Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3, Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3, Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
Aug 1, 2015 → Apr 1, 2020
About Everolimus (Afinitor®)
Everolimus (Afinitor®) is a phase 2 stage product being developed by Novartis for Poorly Differentiated Malignant Neuroendocrine Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02113800. Target conditions include Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02113800 | Phase 2 | Completed |
Competing Products
1 competing product in Poorly Differentiated Malignant Neuroendocrine Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Cabozantinib S-malate | Exelixis | Phase 2 | 49 |